MetabolicIn Stock
Retatrutide
Triple Receptor Agonist
10mg · Lyophilised Powder
$89.00
Retatrutide is a novel investigational compound acting as a triple agonist at GLP-1, GIP, and glucagon receptors. Research suggests significant metabolic modulation, making it one of the most studied peptides in contemporary obesity and metabolic research.
Form
Lyophilised Powder
Purity
≥99% (HPLC)
Storage
2–8°C / 36–46°F
Use
Research Only
1
Secure checkout via PayID · Free shipping over $150
Research Overview
Retatrutide (LY3437943) is a triple agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. This tri-receptor approach represents a novel mechanism investigated for its potential impact on body weight regulation and metabolic parameters.
In a pivotal Phase 2 clinical trial published in the New England Journal of Medicine (2023), participants receiving retatrutide demonstrated dose-dependent reductions in body weight over 24 weeks, with the highest dose group showing mean weight reduction that exceeded previous single or dual agonist compounds.
The compound's mechanism involves amplified satiety signaling through GLP-1R activation, enhanced insulin secretion via GIP receptor engagement, and increased energy expenditure through glucagon receptor stimulation — creating a synergistic metabolic effect not achievable through single-target approaches.
All research applications require qualified laboratory settings and appropriate institutional oversight. This compound is for research use only.
Research Use Only
For in vitro research and laboratory use only. Not approved by the TGA, FDA, or any regulatory authority for human or veterinary use. By purchasing, you confirm you are a qualified researcher using this compound solely for lawful scientific research.
